$ABSI

6 stories mentioning ABSIUpdated 48d ago

Every FINWIRES story that references ABSI, newest first.

Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says

Absci's (ABSI) ABS-201 showed a favorable early safety profile, with no serious adverse events, and pharmacokinetic data supporting a potential two- to three-injection regimen over six months, Truist said in a note on Wednesday.ABS-201 is an anti-prolactin receptor antibody being developed for the treatment of androgenetic alopecia.Truist said the interim phase 1 results represent a de-risking event for the program and that it is now looking ahead to proof-of-concept efficacy data expected in H2.The convenience of that dosing schedule, if supported by future efficacy readouts, could position ABS-201 as a preferred option in the hair growth space, the note said.Truist kept its Buy rating and $11 price target on the stock.Shares of Absci surged 35% in Wednesday afternoon trading.Price: $10.02, Change: $+2.61, Percent Change: +35.22%

$ABSI

Wire48d ago

Top Midday Gainers

Pulsenmore (PLSM) said Wednesday it is partnering with Ouma Health to expand access to remote prenatal care in the US.Shares soared 160% as intraday trading volume catapulted to over 48.6 million from a daily average of about 18,000.Absci (ABSI) said it has priced its underwritten offering of about 13.5 million shares at $7.41 each to raise about $100 million. The offering includes participation from Eli Lilly (LLY).Shares surged 35% amid a jump in intraday trading volume to over 26.4 million from a daily average of almost 5 million.Agility Robotics is set to go public via a merger with blank check firm Churchill Capital XI (CCXI) in a deal valuing the robot maker at $2.5 billion, the companies said Wednesday.Shares jumped 17% following a rise in intraday trading volume to over 11.3 million from a daily average of about 22,000.Price: $9.02, Change: $+5.61, Percent Change: +164.52%

$ABSI$CCXI$PLSM

Sectors49d ago

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.07% higher and the iShares Biotechnology ETF (IBB) flat.Absci (ABSI) stock was up more than 28% after the company priced its underwritten offering of 13.5 million shares at $7.41 each, expecting to raise $100 million in gross proceeds. The financing includes participation from Eli Lilly (LLY), Absci said.Natera (NTRA) shares were up more than 3% after the company said it has secured regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency for its Signatera molecular residual disease, or MRD, test for use in patients with colorectal cancer.ADC Therapeutics (ADCT) stock was down more than 2% after the company said it will reduce its global workforce by about 17% as it shifts resources toward the Zynlonta franchise and seeks operational efficiencies.

$ABSI$ADCT$IBB$NTRA$XLV

Sectors49d ago

Sector Update: Healthcare

Healthcare stocks were advancing premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Absci (ABSI) stock was up 20% after the company priced its underwritten offering of 13.5 million shares at $7.41 apiece, expecting to raise $100 million in gross proceeds. The financing includes participation from Eli Lilly (LLY), Absci said.

$ABSI$LLY

Wire68d ago

Absci Shares Rise After Leerink Partners Initiates Coverage at Outperform

Absci (ABSI) shares were up roughly 18% in Thursday trading after Leerink Partners initiated coverage of the stock with an outperform rating and $12 price target.Intraday trading volume stood at more than 6.2 million shares, against a daily average of roughly 4.7 million shares.Price: $7.02, Change: $+1.08, Percent Change: +18.18%

$ABSI

Research69d ago

Leerink Partners Initiates Absci at Outperform With $12 Price Target

Absci (ABSI) has an average rating of buy and mean price target of $8.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$ABSI

Track with the FINWIRES app suite

FolioX

Track ABSI in your portfolio

WheelAI

Analyze ABSI options with the wheel strategy

StockInsider

See market sentiment on ABSI